David Colpman
Director/Board Member chez ELUTIA INC.
Fortune : 9 759 $ au 31/03/2024
Profil
David Colpman is currently an Independent Director at Elutia, Inc., a Director at HighCape Capital Acquisition Corp.
II, and a Director at Oak Hill Bio Corp.
He is also a Member of the Royal Pharmaceutical Society of Great Britain, an Advisor at HighCape Partners Management LLC, and an Advisor at Science Creates Ventures LLP.
Previously, he served as an Independent Director at Orexo AB, a Director at HRA Pharma Development SARL, a Non-Executive Director at Forendo Pharma Oy, and an Independent Director at HighCape Capital Acquisition Corp.
He was also a Senior Vice President at Shire Plc, a Principal at GlaxoWellcome, and a Managing Partner at Colpman Consulting Ltd.
Mr. Colpman received his undergraduate degree from the University of Portsmouth in 1984.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ELUTIA INC CLASS A
0,02% | 08/06/2023 | 3 098 ( 0,02% ) | 9 759 $ | 31/03/2024 |
Postes actifs de David Colpman
| Sociétés | Poste | Début |
|---|---|---|
| ELUTIA INC. | Director/Board Member | 20/10/2022 |
Royal Pharmaceutical Society of Great Britain
 Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Corporate Officer/Principal | - |
HighCape Capital Acquisition Corp. II
 HighCape Capital Acquisition Corp. II Financial ConglomeratesFinance HighCape Capital Acquisition Corp. II operates as a blank check company. Its objective is effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination. The company was founded on February 9, 2021 and is headquartered in New York, NY. | Director/Board Member | - |
Oak Hill Bio Corp.
 Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | Director/Board Member | 12/04/2022 |
HighCape Partners Management LLC
 HighCape Partners Management LLC Investment ManagersFinance HighCape Partners Management LLC (HighCape Partners) is a private equity firm founded in 2013 by Kevin Rakin and Matt Zuga. The firm headquartered in Westport, Connecticut.. | Consultant / Advisor | - |
Science Creates Ventures
 Science Creates Ventures Investment ManagersFinance Science Creates Ventures LLP (Science Creates Ventures) is a venture capital firm founded in 2020 by Harry Destecroix and Jonathan Craton. The firm is headquartered in Bristol, United Kingdom. | Consultant / Advisor | - |
Anciens postes connus de David Colpman
| Sociétés | Poste | Fin |
|---|---|---|
HRA Pharma Development SARL
 HRA Pharma Development SARL Pharmaceuticals: MajorHealth Technology HRA Pharma Development SARL develops medicines and products for women's health and endocrinology. It offers emergency contraception, uterine fibroids, regular contraception, intimate health, genital herpes, and Lysosafe service. The company was founded by André Ulmann in 1996 and is headquartered in Châtillon, France. | Director/Board Member | 01/04/2022 |
| HIGE CAPI | Director/Board Member | 10/06/2021 |
Colpman Consulting Ltd.
 Colpman Consulting Ltd. Financial ConglomeratesFinance Colpman Consulting Ltd. provides financial advisory services. The private company is based in Hampshire, UK. | Corporate Officer/Principal | 01/03/2020 |
| ░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formation de David Colpman
| University of Portsmouth | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| OREXO AB | Health Technology |
| ELUTIA INC. | Health Technology |
| Entreprise privées | 12 |
|---|---|
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Royal Pharmaceutical Society of Great Britain
Royal Pharmaceutical Society of Great Britain Miscellaneous Commercial ServicesCommercial Services The Royal Pharmaceutical Society of Great Britain provides expertise and support to its member pharmacists. The private company is based in Great Britain. Alex MacKinnon has been the CEO of the British company since 2010. | Commercial Services |
| GlaxoWellcome /Pharmocology Unit/ | Commercial Services |
Purdue Pharma (Canada)
 Purdue Pharma (Canada) Pharmaceuticals: MajorHealth Technology Purdue Pharma (Canada) manufactures and markets pharmaceutical products. It products for the treatment of pain, respiratory disease, gastrointestinal disorders, and infection control. The firm include laxatives, bronchodilators, antiseptics, and analgesics. Purdue Pharma is headquartered in Pickering, Canada | Health Technology |
HRA Pharma Development SARL
HRA Pharma Development SARL Pharmaceuticals: MajorHealth Technology HRA Pharma Development SARL develops medicines and products for women's health and endocrinology. It offers emergency contraception, uterine fibroids, regular contraception, intimate health, genital herpes, and Lysosafe service. The company was founded by André Ulmann in 1996 and is headquartered in Châtillon, France. | Health Technology |
HighCape Partners Management LLC
HighCape Partners Management LLC Investment ManagersFinance HighCape Partners Management LLC (HighCape Partners) is a private equity firm founded in 2013 by Kevin Rakin and Matt Zuga. The firm headquartered in Westport, Connecticut.. | Finance |
Forendo Pharma Oy
 Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Health Technology |
Colpman Consulting Ltd.
Colpman Consulting Ltd. Financial ConglomeratesFinance Colpman Consulting Ltd. provides financial advisory services. The private company is based in Hampshire, UK. | Finance |
HighCape Capital Acquisition Corp.
 HighCape Capital Acquisition Corp. Financial ConglomeratesFinance HighCape Capital Acquisition Corp. operates as a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses for its initial business. The company was founded on June 10, 2020 and is headquartered in New York, NY. | Finance |
HighCape Capital Acquisition Corp. II
HighCape Capital Acquisition Corp. II Financial ConglomeratesFinance HighCape Capital Acquisition Corp. II operates as a blank check company. Its objective is effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination. The company was founded on February 9, 2021 and is headquartered in New York, NY. | Finance |
Science Creates Ventures
Science Creates Ventures Investment ManagersFinance Science Creates Ventures LLP (Science Creates Ventures) is a venture capital firm founded in 2020 by Harry Destecroix and Jonathan Craton. The firm is headquartered in Bristol, United Kingdom. | Finance |
Oak Hill Bio Corp.
Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | Commercial Services |
